INT Medical(01501.HK): Proposed A-share Issuance, Pre-listing Tutoring Filing Accepted by Shanghai Securities Regulatory Bureau
NewTimeSpace News: Shanghai INT Medical Instruments Co., Ltd. (01501.HK) released an inside information announcement on June 12, 2026, proposing to issue A-shares on stock exchanges in China. The Board announced that the Company has appointed Guotai Haitong Securities Co., Ltd. as the pre-listing tutor for the proposed A-share issuance and entered into a tutoring agreement. The pre-listing tutoring filing has been accepted by the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission.
The Company stated that the acceptance of the pre-listing tutoring filing does not mean that the Company has met the criteria for submitting the A-share issuance application or filed an application with relevant domestic stock exchanges. As at the date of this announcement, the structure of the proposed A-share issuance has not been determined. Save for the pre-listing tutoring filing submitted to the Shanghai Securities Regulatory Bureau, no application for approval of the proposed A-share issuance has been filed with any regulatory authority in China or elsewhere.
The Company reminds shareholders and potential investors that the proposed A-share issuance is subject to various conditions and factors, and is conditional upon obtaining formal approvals and consents from the Board, shareholders and relevant Chinese regulatory authorities. There is no guarantee that the proposed A-share issuance will be implemented, nor any certainty as to the timeline thereof.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
